Lapsed Oct 25, 2024 on the fee record · High confidence
20-year base term ends Jun 24, 2033
Second maintenance fee unpaid; grace period ended.
Jun 24, 2013
Oct 25, 2024
Oct 25, 2016
Jun 24, 2033
Its term would have run to Jun 24, 2033: its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. Confidence: High. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jun 24, 2013, when application 13/925,509, the earliest non-provisional in its chain, was filed (this one was filed Jun 7, 2016) | Jun 24, 2033 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 8,906,951, US 9,198,898, US 9,381,188) | resolves to Jun 24, 2033, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 3 maintenance fees paid | lapsed Oct 25, 2024 | High confidence |
| Computed term end | The steps above, in order | Oct 25, 2024 | High confidence |
This family
| US 8,906,951 | In force Jun 2033 | Jun 2033 |
| US 9,198,898 | Lapsed on the fee record Dec 2023 | Dec 2023 |
| Application PCT/US2014/043811 | PCT application no patent term | no patent term |
| US 9,381,188 | Lapsed on the fee record Jul 2024 | Jul 2024 |
| US 9,486,439 | Lapsed on the fee record Nov 2024 | Nov 2024 |
| US 9,474,741 | this patent Oct 2024 | Oct 2024 |
| US 9,737,507 | Lapsed on the fee record Aug 2025 | Aug 2025 |
| US 9,737,508 | Lapsed on the fee record Aug 2025 | Aug 2025 |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jul 6, 2016 Reel 39197, frame 765 | Tigercat Pharma, Inc. | Menlo Therapeutics Inc. | Change of Name |
| May 5, 2017 Reel 42259, frame 57 | Zhang, Xiaoming; Schnipper, Edward F.; Perlman, Andrew J.; Larrick, James W. | Tigercat Pharma, Inc. | Assignment of Assignor's Interest |
| Mar 9, 2020 Reel 52130, frame 980 | Menlo Therapeutics Inc. | Perceptive Credit Holdings II, LP | Patent Security Agreement |
| Dec 1, 2020 Reel 54558, frame 437 | Menlo Therapeutics Inc. | Vyne Therapeutics Inc. | Change of Name |
| Sep 20, 2021 Reel 57531, frame 986 | Perceptive Credit Holdings II, LP | Vyne Therapeutics Inc. (F/K/A Menlo Therapeutics Inc. and Successor-in-Interest to Vyne Pharmaceuticals Ltd., F/K/A Foamix Pharmaceuticals Ltd.) | Release of Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
A terminal disclaimer resolved from the filed document, referencing US 8,906,951, US 9,198,898, US 9,381,188, ends no earlier than this term, so it caps nothing.